Lazertinib is a medication used in this trial for patients with advanced or metastatic non-small cell lung cancer that has specific mutations. It is being studied to see how well it works in combination with another medication after the cancer has progressed despite previous treatments.

Amivantamab is another medication involved in this trial. It is used to treat patients with non-small cell lung cancer that has certain genetic changes. The study is comparing two ways of giving this medication: one is through a subcutaneous injection, which means it is injected under the skin, and the other is through an intravenous infusion, which means it is given directly into a vein. The goal is to see if the subcutaneous method is as effective as the intravenous method.

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer – This is a type of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. These mutations lead to uncontrolled cell growth and division, contributing to the development and progression of cancer. The disease is classified as advanced or metastatic when it has spread beyond the lungs to other parts of the body. Symptoms may include persistent cough, chest pain, and difficulty breathing. As the cancer progresses, it can affect various organs and systems, leading to a decline in overall health. The focus of research often involves understanding the behavior of these mutations and finding effective ways to manage the disease.